Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces New Chief Strategy and Innovation Officer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports First-Quarter 2024 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Second-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
From Pfizer Inc.
Via Business Wire
Tickers PFE
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
From Pfizer Inc.
Via Business Wire
Tickers PFE
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.